TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Monday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Up 1.2 %

NASDAQ TXMD opened at $1.74 on Monday. The stock’s 50-day moving average price is $2.00 and its 200-day moving average price is $2.19. TherapeuticsMD has a 52 week low of $1.67 and a 52 week high of $4.35.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Friday, May 10th. The company reported ($0.07) EPS for the quarter. The firm had revenue of $0.31 million during the quarter.

Institutional Trading of TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC bought a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned approximately 0.21% of TherapeuticsMD at the end of the most recent quarter. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.